Heart Failure Duration, Cardiac Remodeling, Dysfunction, and Hemodynamic Severity in HFpEF and HFmrEF: Insights From REDUCE LAP-HF II [0.03%]
HFpEF和HFmrEF中HF持续时间、心脏重塑、功能障碍以及血流动力学严重程度：来自REDUCE LAP-HF II研究的启示
Shunichi Doi,Sho Kazui,Naoyuki Akashi et al.
Shunichi Doi et al.
Background: Pathophysiologic features associated with increased risk in heart failure with preserved ejection fraction (HFpEF) may reflect distinct phenotypes or disease stages related to heart failure (HF) duration. ...
Long-Term Outcomes From a Decade of Donation After Circulatory Death Heart Transplantation in Australia [0.03%]
十年来澳大利亚心脏死亡捐献者心脏移植的长期结果
Yashutosh Joshi,Sarah Scheuer,Hong Chew et al.
Yashutosh Joshi et al.
Background: Heart transplantation (HT) from donation after circulatory death (DCD) donors has successfully expanded the donor pool with excellent short-term survival outcomes, but there is uncertainty regarding long-term ...
Genotype Predicts Heart Failure Independent of LVEF, Peak VO2, and NT-proBNP Levels in Hypertrophic Cardiomyopathy [0.03%]
基因型可独立于左室射血分数、峰值摄氧量及NT-proBNP水平预测肥厚性心肌病患者的心力衰竭风险
Athanasios Bakalakos,Alexandros Protonotarios,Menelaos Pavlou et al.
Athanasios Bakalakos et al.
Background: Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by left ventricular hypertrophy and progression to heart failure (HF). Approximately 40% of cases are caused by variants in genes encodi...
Survival Outcomes in Middle-Aged and Older Patients With Advanced Heart Failure: A Propensity-Matched Analysis of HeartMate 3 LVAD and Heart Transplant Using MOMENTUM 3 and UNOS Registry [0.03%]
植入HeartMate 3心室辅助装置与心脏移植治疗晚期心力衰竭患者的生存比较：MOMENTUM 3试验和UNOS登记研究的事后倾向性匹配分析
Nir Uriel,Gabriel T Sayer,Paolo C Colombo et al.
Nir Uriel et al.
Background: Heart failure (HF) increases in prevalence with age. For patients with advanced HF, both durable left ventricular assist devices (LVADs) and heart transplantation (HT) can improve longevity and quality of life...
Pulmonary Artery Pressure Rises Before Atrial Fibrillation Onset in CardioMEMS Monitoring [0.03%]
在CardioMEMS监测中肺动脉压在房颤发生前上升
Alexandria Danyluk,Ivan Nenadic,Marat Fudim
Alexandria Danyluk
Safety and Feasibility of IVC Flow Modulation With the Doraya in Acute Decompensated Heart Failure [0.03%]
急性心力衰竭时使用Doraya进行下腔静脉血流调节的安全性和可行性
Lucas S Zier,David A Baran,Rami Kahwash et al.
Lucas S Zier et al.
Donor-Derived Cell-Free DNA as a Prognostic Biomarker After Heart Transplantation: The DEFINE-HT Study [0.03%]
基于供者来源的细胞游离DNA作为心脏移植术后的预后生物标志物：DEFINE-HT研究
Palak Shah,Paul J Kim,Kelly H Schlendorf et al.
Palak Shah et al.
Background: Measurement of donor-derived cell-free DNA fraction (dd-cfDNA%) and donor quantity score (DQS) is a noninvasive biomarker of acute rejection in heart transplantation (HT). Its prognostic value beyond histopath...
Echo-Based, Artificial Intelligence Algorithm Identifies Future Heart Failure Cases: A Blinded, Retrospective Clinical Trial Report [0.03%]
基于回声的人工智能算法识别未来心力衰竭病例：一项双盲回顾性临床试验报告
Yih-Kai Chan,Geoff A Strange,David Playford et al.
Yih-Kai Chan et al.
Screening and Treatment Using a Risk-Based Approach with NT-proBNP Guidance in Diabetes Mellitus: The STRONG-DM Pilot Study [0.03%]
基于风险的筛查和治疗：使用NT-proBNP指导的糖尿病心肾保护计划STRONG-DMPilot研究
Vinayak Subramanian,Kershaw V Patel,Jude Moutchia Suh et al.
Vinayak Subramanian et al.
Background: Adults with type 2 diabetes mellitus (T2DM) have an elevated risk for developing heart failure (HF), but prescription rates of preventive therapies remain low. ...
REPLY: Mind the Gap: Challenges Moving Trial Doses Into Practice [0.03%]
关于试验剂量在临床实践中的应用挑战的回复：需要注意剂量差距问题
Misato Chimura,Pardeep S Jhund,John J V McMurray
Misato Chimura